DEADLINE SNAIL & SLUG PASTE

Main information

  • Trade name:
  • DEADLINE SNAIL & SLUG PASTE
  • Class:
  • AgChem
  • Medicine domain:
  • Plants
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • DEADLINE SNAIL & SLUG PASTE
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • FLOWER | FRUIT CROP OR TREE | HOME GARDEN USE - GENERAL | ORNAMENTAL | ORNAMENTAL SEEDLING | VEGETABLE | VEGETABLE SEEDLING | BA
  • Therapeutic area:
  • MOLLUSCICIDE
  • Therapeutic indications:
  • COMMON SLUG | SNAIL | BRADYBAENA SIMILARIS | DEROCERAS CARUANAE | HELIX ASPERSA | SIGMURETHRA | THEBA PISANA

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Archived
  • Authorization number:
  • 33242
  • Last update:
  • 09-08-2016

6-12-2018

Application deadlines in 2018

Application deadlines in 2018

The Danish Medicines Agency will be closed between Christmas and New Year from 22 December 2018 to 1 January 2019, both days inclusive. This means that enquiries made to the Danish Medicines Agency, with a few exceptions, will not be read and replied during this period. On this page, you can find the deadlines that apply to applications in the Danish Medicines Agency's area in 2018.

Danish Medicines Agency

5-12-2018

Pesticides: new deadline for cumulative risk assessments

Pesticides: new deadline for cumulative risk assessments

Pesticides: new deadline for cumulative risk assessments

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

25-10-2018

Nutrition Facts Label Reboot: A Tale of Two Labels

Nutrition Facts Label Reboot: A Tale of Two Labels

The Nutrition Facts Label (NFL) on packages consumers look at when they’re buying groceries or preparing a meal has undergone a makeover. The U.S. Food and Drug Administration (FDA) has changed it to reflect updated scientific findings and help consumers make better-informed choices about the foods their families eat. Until the deadlines, consumers may see two different versions on the products they buy: the original label they’ve been using, as well as the new label. The Consumer Update will emphasize...

FDA - U.S. Food and Drug Administration

5-10-2018

Consumer Alert: Sprout Creek Farm “Margie” Cheese Batch Recalled

Consumer Alert: Sprout Creek Farm “Margie” Cheese Batch Recalled

Today the New York State Department of Agriculture and Markets alerted consumers to a pasteurization problem with one of Sprout Creek Farm's pasteurized cow's milk cheeses, "Margie," made on 8/28/2018. Sprout Creek Farm is located in Poughkeepsie, NY. The reason for the recall is the air temperature at the start and end of the pasteurization process is required to be above 150deg F per the Grade "A" Pasteurized Milk Ordinance; the batch in question did not meet that standard. The recall pertains only to...

FDA - U.S. Food and Drug Administration

29-8-2018

Outcome of the public consultation on a draft protocol for the Scientific Opinion on dietary sugars

Outcome of the public consultation on a draft protocol for the Scientific Opinion on dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on a draft protocol for the Scientific Opinion on free sugars from all dietary sources, prepared by the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel), supported by the ad‐hoc Working Group on Sugars. The draft protocol was endorsed by the Panel for public consultation at its plenary meeti...

Europe - EFSA - European Food Safety Authority Publications

30-5-2018

12 applications for allocation of special funds related to medicinal cannabis

12 applications for allocation of special funds related to medicinal cannabis

The application deadline for the second allocation of special funds for accumulation of scientific knowledge in regard to the medicinal cannabis pilot programme has now expired. The Danish Medicines Agency received 12 applications.

Danish Medicines Agency

3-7-2017

The Icelandic Medicines Agency wishes to recruit experts to its Licencing Unit

The Icelandic Medicines Agency wishes to recruit experts to its Licencing Unit

The Agency advertises two vacancies for experts in its Quality Assessment Team. The Agency is looking for strong candidates who are willing to work on challenging and interesting tasks. Each vacancy is a full position (100%). Application deadline is up to and including 16 July 2017.

IMA - Icelandic Medicines Agency

14-11-2016

Deadline for submitting a clinical trial application (CTA) in 2016 is 9 December

Deadline for submitting a clinical trial application (CTA) in 2016 is 9 December

IMA will not confirm receipt of clinical trial applications or substantial amendments received after 9 December 2016 until after 2 January 2017.

IMA - Icelandic Medicines Agency

12-5-2016

Nine applications for funds earmarked for research in HPV adverse reactions

Nine applications for funds earmarked for research in HPV adverse reactions

The Danish Parliament has earmarked an amount of DKK 7 million for research into possible adverse reactions from the HPV vaccines. The deadline for applications has expired and the applications will now be reviewed by Innovation Fund Denmark.

Danish Medicines Agency

21-1-2015

Consultation on transparency in clinical trials

Consultation on transparency in clinical trials

The European Medicines Agency (EMA) has launched a public consultation on how to implement the transparency requirements of the new EU Clinical Trials Regulation. Deadline on 18 February.

Danish Medicines Agency

2-2-2009

Consultation responses on the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09

Consultation responses on the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09

The Danish Medicines Agency's assessment of the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09 for the treatment of cardiovascular diseases has been submitted for consultation with 11 December 2008 as the consultation deadline.

Danish Medicines Agency

19-12-2008

Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)

Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)

The Danish Medicines Agency's assessment of the future reimbursement status of the dihydropyridine calcium antagonists (C08CA) were submitted for consultation with 11 November 2008 as the consultation deadline.

Danish Medicines Agency

21-11-2008

Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases

Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases

The Reimbursement Committee’s additional recommendation concerning the future reimbursement status of medicinal products for cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensives) was submitted for consultation with 19 September 2008 as the consultation deadline

Danish Medicines Agency

14-12-2018

Dengvaxia (Sanofi Pasteur)

Dengvaxia (Sanofi Pasteur)

Dengvaxia (Active substance: dengue tetravalent vaccine (live, attenuated)) - Centralised - Authorisation - Commission Decision (2018)8933 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4171

Europe -DG Health and Food Safety

7-8-2018

Intanza (Sanofi Pasteur Europe)

Intanza (Sanofi Pasteur Europe)

Intanza (Active substance: Influenza Vaccine (split virion, inactivated)) - Centralised - Withdrawal - Commission Decision (2018)5426 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety